Skip to content

Kaleab Abebe

    • 14h-indexImpact measure calculated using publication and citation counts. Updated daily.
    • 1037CitationsNumber of citations received by Kaleab's publications. Updated daily.

    Co-authors (308)

    • Susan Spillane

    Publications (5)

    • Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease

      • Torres V
      • Abebe K
      • Schrier R
      • et al.
      N/AReaders
      N/ACitations
      Get full text
    • Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment

      • McGowan I
      • Dezzutti C
      • Siegel A
      • et al.
      N/AReaders
      N/ACitations
      Get full text
    • Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.

      • Irazabal M
      • Abebe K
      • Bae K
      • et al.
      N/AReaders
      N/ACitations
      Get full text
    • A phase 1 randomized, open label, rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of three formulations of tenofovir 1% Gel (the CHARM-01 study)

      • Mcgowan I
      • Cranston R
      • Duffill K
      • et al.
      N/AReaders
      N/ACitations
      Get full text
    • Liver involvement in early autosomal-dominant polycystic kidney disease

      • Hogan M
      • Abebe K
      • Torres V
      • et al.
      N/AReaders
      N/ACitations
      Get full text